Announcement
25 Mar 2021
On 25 March 2021, BARDA provided USD 32 million funding to Janssen Pharmaceutical Companies of Johnson and Johnson to support their efforts in expanding Phase 2a COVID-19 vaccine trial to include adolescents ages 12-17.
Source
Sign in to access
Number of interventions
1
1 certainly harmful
0 likely harmful
0 liberalising
List of interventions
Implementation date
25 Mar 2021
Revocation date:
No revocation date
Updated: 25 Mar 2021
State aid, unspecified
In force
On 25 March 2021, the U.S. Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA) announced providing USD 32 million funding to Janssen Pharma...
Sign in to see more
Related State Acts
13 Nov 2020
United States of America: BARDA provides $454.3 million funding to Janssen Pharmaceuticals to support their COVID-19 vaccine Phase 3 clinical trials in adults
21 Aug 2020
United States of America: BARDA provides $85.3 million funding to Janssen Pharmaceuticals to support Janssen’s COVID-19 vaccine phase 2 clinical trials and additional non-clinical studies
05 Aug 2020
United States of America: BARDA and DOD collaborates with Janssen Pharmaceuticals for the production of investigational COVID-19 vaccine doses
27 Mar 2020
United States of America: BARDA provides $435 million funding to Janssen Pharmaceuticals to support Janssen’s vaccine candidate through phase 3 clinical trials
11 Feb 2020
United States of America: BARDA collaborates with Janssen Pharmaceuticals to accelerate clinical trials and manufacturing of COVID-19 vaccine
Threads
See all
This state act is not part of any Thread yet.